Schering Aktiengesellschaft

Jenapharm Gmbh & Co. Kg

Bayer Schering Pharma Ag

Gudrun Reddersen

Walter Elger

Birgitt Schneider

Sigfrid Schwarz

Alexander Hillisch

Peter Droescher

Margit Richter

Dirk Kosemund

Sven Ring

Ulrich Bothe

Michael Oettel

Olaf Peters

Gerd Schubert

Bernd Menzenbach

Matti Lehtinen

Ralf Wyrwa

Hans-Udo Schweikert

Ina Thieme

Holger Zimmermann

Thomas Michel

Ina Scherlitz-Hofmann

Gerd M&uuml;ller

Pekka Lähteenmäki

Christel Siemann

Hans-Joachim Siemann

Birgit Schneider

By Margit Lucas, Heir

Hans-Joachim Siemann, Deceased

By Frank Siemann, Heir

The invention relates to new compounds of general formula I, their production and pharmaceutical preparations that contain these compounds. The compounds according to the invention are preferably used for female birth control and for HRT.

Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy

The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action.

Estradiol prodrugs

New 17&#x3b1;-fluorosteroid compounds of formula (I) are disclosed: wherein Rdenotes H or methyl; Rand Reach denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character so that they act as inhibitors for 5&#x3b1;-reductase and as high potency gestagens. Pharmaceutical compositions containing them are disclosed. They are suitable for treatment of conditions, which are caused by high levels of androgen in organs and tissues. These new compounds can be used in combination with other hormonal substances, such as estrogens, testosterone and other androgens, as contraceptives and for other applications.

17&#x3b1;-fluorosteroids, pharmaceutical compositions containing 17&#x3b1;-fluorosteroids and a method of making them

The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.

Use of biogenic estrogen sulfamates for hormone replacement therapy

The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formulaR&#x2014;SO&#x2014;O&#x2014; The preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). They exhibit a low hepatic estrogenity.

Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives

C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds

Estra-1,3,5(10)-trien derivatives, processes for their preparation and

The invention relates to new sulfamate derivatives of 1,3,5(10)-estratriene derivatives of the general formula I ##STR1## wherein the 3-sulfamate moiety is acylated, sulfonated or amidosulfonated. Furthermore, methods for the production of the compound and pharmaceutical preparations containing this compound are described. The compounds according to the invention have an estrogenic effect.

Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for

Growing community of inventors

Jena, Germany

Gudrun Reddersen